...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: What's the deal with Zenith?

Explain how the debt is paid to Zenith if BOM2 fails. I assume what we are talking about is somehow Zenith is able to loan Resverlogix enough money for BOM2 which would be in the order of ~$40Mil. And again we're assuming that Shezhen Hepalink will fund the other ~$40 Mil for an ~$80 Mil required for BOM2.

The question is how long will it take for Zenith to accumulate ~$40 Mil by way of the 8% Royalty Continue Value Rights? And how long will it take BP and ZEN-3694 to complete Phase 3 for the indications identified on Slide 39 of the Presentation? And we also have to assume they will be successful. I'm not sure any part of this is feasible!!! Or am I understanding this all wrong?

 

Koo

 

Share
New Message
Please login to post a reply